Featuring online engagement, assessment and scheduling, as well as in-person clinical testing and logistics, TourHealth is a scalable COVID-19 testing solution that promises rapid results.
The TourHealth partnership has been awarded a contract by the State of Florida to provide two semi-permanent testing sites in city of Miami and Miami Beach.
At each site, TourHealth will be able to process up to 625 tests per day for a total of 1,250 tests daily.
In Utah, the TourHealth partnership was selected as one of two vendors approved for a multi-vendor contract vehicle to provide scheduling, call center and test collection relating to COVID-19 testing for state agencies, local governments and educational institutions.
Under the TourHealth partnership, NIC will provide its Gov2Go technology solution, a mobile platform and personal government assistant, for citizen engagement, assessment and scheduling purposes.
Impact Health will supply credentialled clinical professionals to staff the testing units and provide testing results quickly and securely to individuals and government, integrating results with government contact tracing programs. Next Marketing will be responsible for onsite logistics, including supplying mobile testing units, site design, signage and operational support, as applicable.
NIC (NASDAQ: EGOV) is a leading digital government solutions and payments company, serving more than 7,000 federal, state and local government agencies across the nation.
Impact Health is in providing field-based health and wellness services and has led efforts to combat the COVID-19 pandemic through temperature scanning and testing with various FDA/EUA approved kits.
Impact Health supports both private and public sector clients including Yale New Haven Health, Ashley Furniture, CBS Broadcasting and the State of Kansas.
Next Marketing is in developing, executing and managing mobile tour solutions for corporate and government clients including the US Air Force, Air National Guard, General Motors, and Continental Tire.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma